FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Exjade (deferasirox) by Novartis, expanding the labeling for treating chronic iron overload due to blood transfusion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transfusion-dependent Iron Overload

Drugs mentioned

• Exjade (deferasirox)

Snippet

SUPPL AP for EXJADE (DEFERASIROX)